San Diego, CA – According to filings with the U.S. Securities and Exchange Commission, Replicate Bioscience is raising $40,000,000.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Nathaniel Wang played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Replicate Bioscience

At Replicate, we are focused on staying ahead of the curve staying ahead of tumor resistance that occurs over time in patients on immuno-oncology regimens because cancer knows no boundaries. It is estimated that 90% of cancer related deaths come from drug resistance caused by tumor evolution. We have created a solution to a huge problem where no viable solutions or therapies exist. Replicate is focused on creating novel oncology treatments to prevent and reverse drug resistance through our proprietary self-replicating RNA platform called SynRGY. By deploying our SynRGY technology, we aim to design novel treatments that prevent the occurrence of drug resistance and create solutions that enhance the effectiveness of many immuno-oncology regimens.

To learn more about Replicate Bioscience, visit http://replicatebioscience.com/

Contact:
Nathaniel Wang, Chief Executive Officer
619-786-7702

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved